(PDF) Oncolytic Viruses by Christine E. Engeland

This is the PDF eBook version for Oncolytic Viruses by Christine E. Engeland

Table of Contents

1. Introduction to Oncolytic Virotherapy
Christine E. Engeland and John C. Bell
2. Methods for Modification of Therapeutic Viruses
Claudia AP Hill, Luca Bau, and Robert Carlisle
3. Tumor Targeting of Oncolytic Adenoviruses using Bispecific Adapter Proteins
Julia Niemann and Florian Kuhnel
4. Development of Entry-targeted Oncolytic Measles Viruses
Michael D. Muhlebach and Roberto Cattaneo
5. Insert Stability and In Vivo Testing of MicroRNA-Detargeted Oncolytic Picornaviruses
Autumn J Schulze
6. Ex vivo Virotherapy with Myxoma Virus to Treat Cancer
Nancy Y. Villa, Lina S. Franco, and Grant McFadden
7. Immunomodulation in Oncolytic Measles Virotherapy
Laura Dietz and Christine E. Engeland
8. A Functional Assay to Determine the Capacity of Oncolytic Viruses to Induce Immunogenic Tumor Cell Death
Tiphaine Delaunay, Carole Achard, Marc Gregoire, Frederic Tangy, Nicolas Boisgerault, and Jean-Francois Fonteneau
9. Design and Production of Newcastle Disease Virus for Intratumoral Immunomodulation
Gayathri Vijayakumar and Dmitriy Zamarin
10. Analysis of Immunological Treatment Effects of Virotherapy in Tumor Tissue
Krishna Das, Carles Urbiola, Bart Spiesschaert, Philipp Mueller, and Guido Wollmann
11. Immunohistochemistry for Tumor-infiltrating Immune Cells after Oncolytic Virotherapy
Dipongkor Saha and Samuel D. Rabkin
12. Detection of Tumor Antigen-specific T-cell Responses after Oncolytic Vaccination
Jonathan G. Pol, Byram W. Bridle, and Brian D. Lichty
13. Evaluation of Oncolytic Virus Induced Therapeutic Tumor Vaccination Effects in Murine Tumor Models
Ruta Veinalde
14. Delivery of Oncolytic Reovirus by Cell Carriers
Elizabeth J. Ilett
15. In Vivo Bioimaging for Monitoring Intratumoral Virus Activity
Liesa-Marie Schreiber, Carles Urbiola, Patrik Erlmann, and Guido Wollmann
16. Oncolytic Immunotherapy for Bladder Cancer Using Coxsackie A21 virus: Using a Bladder Tumour Precision-cut Slice Model System to Assess Viral Efficacy
Kate Relph, Nicola Annels, Chris Smith, Marcos Kostalas, and Hardev Pandha
17. Use of Liquid Patient Ascites Fluids as a Pre-clinical Model for Oncolytic Virus Activity
Eleanor M. Scott, Sally Frost, Hena Khalique, Joshua D. Freedman, Len W. Seymour, and Janet Lei-Rossmann
18. Generating Primary Models of Human Cancer to Aid in the Development of Clinically-relevant Oncolytic Viruses
Brian A. Keller, Marie-Eve Wedge, Abera Surendran, and Carolina S. Ilkow
19. Considerations for Clinical Translation of MG1 Maraba Virus
Caroline J. Breitbach
20. Fluorescence in Situ Hybridization (FISH) Detection of Viral Nucleic Acids in Oncolytic H-1 Parvovirus-treated Human Brain Tumors
Irina Kiprianova, Alexandra Just, Barbara Leuchs, Jean Rommelaere, and Assia L. Angelova
21. Mathematical Modeling of Oncolytic Virotherapy